
Hui Yang, M.D., Ph.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Yang
The major focus of Dr. Yang's effort is the translational research of molecular epigenetics in leukemia and MDS. She has worked on the development of new epigenetic therapy for patients with leukemia and MDS at leukemia department of MD Anderson Cancer Center for more than ten years. By targeting DNA methylation and histone acetylation, her preclinical study on the antileukemia activity of the combination of decitabine with HDAC inhibitor valproic acid represented a significant advancement. It served as a basis for clinical application and led to a series of clinical trials. Furthermore, Dr. Yang performed the correlative studies of these clinical trials to identify specific alterations with prognostic value. The use of hypomethylating agents (HMAs) is a standard treatment in patients with high risk MDS. It is also commonly used in AML. However, resistance to HMAs is an almost universal phenomenon. Identify HMAs treatment induced specific alterations in AML and MDS could be used to develop new therapy to overcome HMAs resistance. Her recent work on the immune checkpoints, PD-1/PD-L1 axis, suggests that deregulation of PD-1/PD-L1 axis may contribute the MDS pathogenesis and that induction of PD-1 and PD-1 ligands by HMAs treatment may be involved in HMAs resistance. The blockade of this pathway alone or in combination with HMAs can be a potential therapy in MDS patients. Its application extended to the leukemia clinic and led to a series of ongoing clinical trials.
Read More
Present Title & Affiliation
Primary Appointment
Instructor, Department of Leukemia - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
2001 | Peking University, Beijing, CHN, PHD, Medicine |
1998 | Harbin Medical University, Harbin, CHN, MD, Clinical Medicine |
Postgraduate Training
2002-2006 | Postdoctoral Fellow, Leukemia and MDS, The University of Texas MD Anderson Cancer Center, Houston, TX |
Selected Publications
Peer-Reviewed Articles
- Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(7):1659, 2017. e-Pub 2017. PMID: 28338082.
- Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16(6):1133-1144, 2017. e-Pub 2017. PMID: 28270436.
- Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(2):318-324, 2017. e-Pub 2016. PMID: 27795561.
- Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Bohannan ZS, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl:S67-73, 2016. PMID: 27521329.
- Cabrero M, Wei Y, Yang H, Ganan-Gomez I, Bohannan Z, Colla S, Marchesini M, Bravo GM, Takahashi K, Bueso-Ramos C, Garcia-Manero G. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res 44:1-7, 2016. e-Pub 2016. PMID: 26970171.
- Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol 173(1):161-5, 2016. e-Pub 2015. PMID: 26105212.
- Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, Aird D, Bailey SL, Bhavsar EB, Chan B, Colla S, Corson L, Feala J, Fekkes P, Ichikawa K, Keaney GF, Lee L, Kumar P, Kunii K, MacKenzie C, Matijevic M, Mizui Y, Myint K, Park ES, Puyang X, Selvaraj A, Thomas MP, Tsai J, Wang JY, Warmuth M, Yang H, Zhu P, Garcia-Manero G, Furman RR, Yu L, Smith PG, Buonamici S. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3? Splice Site Selection through Use of a Different Branch Point. Cell Rep 13(5):1033-45, 2015. e-Pub 2015. PMID: 26565915.
- Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 29(7):1458-69, 2015. e-Pub 2015. PMID: 25761935.
- Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J, Zwaan CM, van den Heuvel-Eibrink MM, Kornblau SM, De Bont ES. EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System. Mol Cancer Res 13(6):982-92, 2015. e-Pub 2015. PMID: 25944917.
- Estécio MR, Maddipoti S, Bueso-Ramos C, DiNardo CD, Yang H, Wei Y, Kondo K, Fang Z, Stevenson W, Chang KS, Pierce SA, Bohannan Z, Borthakur G, Kantarjian H, Garcia-Manero G. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol 169(3):344-51, 2015. e-Pub 2015. PMID: 25612675.
- Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell 27(5):644-57, 2015. PMID: 25965571.
- Yang H, Maddipoti S, Quesada A, Bohannan Z, Cabrero Calvo M, Colla S, Wei Y, Estecio M, Wierda W, Bueso-Ramos C, Garcia-Manero G. Analysis of class I and II histone deacetylase gene expression in human leukemia. Leuk Lymphoma 56(12):3426-33, 2015. e-Pub 2015. PMID: 25944469.
- DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol 2(1):e12-20, 2015. e-Pub 2014. PMID: 26687423.
- Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, Pierce SR, Jabbour E, Kantarjian H, Garcia-Manero G. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 167(3):356-65, 2014. e-Pub 2014. PMID: 25066676.
- Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes J, Kantarjian H, Garcia-Manero G. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28(6):1280-8, 2014. e-Pub 2013. PMID: 24270737.
- Liu X, Robinson SN, Setoyama T, Tung SS, D'Abundo L, Shah MY, Yang H, Yvon E, Shah N, Yang H, Konopleva M, Garcia-Manero G, McNiece I, Rezvani K, Calin GA, Shpall EJ, Parmar S. FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. Bone Marrow Transplant 49(6):793-9, 2014. e-Pub 2014. PMID: 24710569.
- Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 73(3):495-501, 2014. e-Pub 2014. PMID: 24435060.
- Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy 16(1):90-100, 2014. e-Pub 2013. PMID: 24480547.
- Gañán-Gómez I, Wei Y, Yang H, Pierce S, Bueso-Ramos C, Calin G, Boyano-Adánez Mdel C, García-Manero G. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest. PLoS One 9(4):e93404, 2014. e-Pub 2014. PMID: 24690917.
- Gañán-Gómez I, Wei Y, Yang H, Boyano-Adánez MC, García-Manero G. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med 65C:750-764, 2013. e-Pub 2013. PMID: 23820265.
- Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberg D, Pierce S, Wang H, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Ganan-Gomez I, Ebert B, Levine R, Kantarjian H, Garcia-Manero G. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia 27(11):2177-86, 2013. e-Pub 2013. PMID: 23538751.
- Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27(10):2081-3, 2013. e-Pub 2013. PMID: 23774633.
- Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia 27(9):1832-40, 2013. e-Pub 2013. PMID: 23765228.
- DiNardo CD, Gharibyan V, Yang H, Wei Y, Pierce S, Kantarjian HM, Garcia-Manero G, Rytting M. Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol 88(9):784-9, 2013. e-Pub 2013. PMID: 23757320.
- Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol 31(20):2548-53, 2013. e-Pub 2013. PMID: 23733767.
- Attieh Y, Geng QR, Dinardo CD, Zheng H, Jia Y, Fang ZH, Gañán-Gómez I, Yang H, Wei Y, Kantarjian H, Garcia-Manero G. Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood 121(19):4009-11, 2013. PMID: 23660862.
- Kuang SQ, Fang Z, Zweidler-McKay PA, Yang H, Wei Y, Gonzalez-Cervantes EA, Boumber Y, Garcia-Manero G. Epigenetic inactivation of notch-hes pathway in human B-cell acute lymphoblastic leukemia. PLoS One 8(4):e61807, 2013. e-Pub 2013. PMID: 23637910.
- Dimicoli S, Wei Y, Bueso-Ramos C, Yang H, Dinardo C, Jia Y, Zheng H, Fang Z, Nguyen M, Pierce S, Chen R, Wang H, Wu C, Garcia-Manero G. Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. PLoS One 8(8):e71120, 2013. e-Pub 2013. PMID: 23976989.
- Sikkema AH, den Dunnen WF, Hulleman E, van Vuurden DG, Garcia-Manero G, Yang H, Scherpen FJ, Kampen KR, Hoving EW, Kamps WA, Diks SH, Peppelenbosch MP, de Bont ES. EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro Oncol 14(9):1125-35, 2012. e-Pub 2012. PMID: 22723427.
- Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 30(18):2204-10, 2012. e-Pub 2012. PMID: 22585696.
- Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 87(1):127-9, 2012. e-Pub 2011. PMID: 22072492.
- Yang H, Fang Z, Wei Y, Hu Y, Calin GA, Kantarjian HM, Garcia-Manero G. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol 86(2):237-8, 2011. PMID: 21264920.
- Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound {beta}-phenylethyl isothiocyanate. Blood 116(15):2732-41, 2010. e-Pub 2010. PMID: 20566897.
- Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy 6(7):976-8, 2010. e-Pub 2010. PMID: 20729640.
- Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 5(6):499-508, 2010. e-Pub 2010. PMID: 20484983.
- Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Tambaro FP, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res 16(15):3923-32, 2010. e-Pub 2010. PMID: 20538760.
- Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 150(1):72-82, 2010. e-Pub 2010. PMID: 20456355.
- Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W, Wang ZZ, Garcia-Manero G. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 115(12):2412-9, 2010. e-Pub 2010. PMID: 20061560.
- Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukemia. Br J Hematol 150, 2010.
- Hoshino K, Quintás-Cardama A, Radich J, Dai H, Yang H, Garcia-Manero G. Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leuk Res 33(10):1361-6, 2009. e-Pub 2009. PMID: 19409613.
- Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 113(9):1892-8, 2009. e-Pub 2008. PMID: 19109226.
- Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, Kantarjian H. Epigenetics of acute lymphocytic leukemia. Semin Hematol 46(1):24-32, 2009. PMID: 19100365.
- Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 14(19):6296-301, 2008. PMID: 18829512.
- Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, Wei Y, Jelinek J, Issa JP, Garcia-Manero G. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22(8):1529-38, 2008. e-Pub 2008. PMID: 18528427.
- Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112(4):981-9, 2008. e-Pub 2008. PMID: 18495956.
- Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111(3):1060-6, 2008. e-Pub 2007. PMID: 17962510.
- Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110(7):2302-8, 2007. e-Pub 2007. PMID: 17596541.
- Amin HM, Hoshino K, Yang H, Lin Q, Lai R, Garcia-Manero G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J Pathol 212(4):402-10, 2007. PMID: 17503411.
- Hoshino K, Quintás-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia 21(5):906-11, 2007. e-Pub 2007. PMID: 17344919.
- Kuang SQ, Ling X, Sanchez-Gonzalez B, Yang H, Andreeff M, Garcia-Manero G. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene 26(10):1439-48, 2007. e-Pub 2006. PMID: 16936778.
- Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10):3271-9, 2006. e-Pub 2006. PMID: 16882711.
- Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM, Garcia-Manero G. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108(4):1174-82, 2006. e-Pub 2006. PMID: 16675713.
- Canalli AA, Yang H, Jeha S, Hoshino K, Sanchez-Gonzalez B, Brandt M, Pierce S, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leuk Res 29(8):881-5, 2005. e-Pub 2005. PMID: 15978938.
- Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res 29(7):739-48, 2005. e-Pub 2005. PMID: 15927669.
- Yang H, Wang SW, Yin HJ. [p21(WAF1) transfection decreases sensitivity of K562 cells to VP-16]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 10(1):31-4, 2002. PMID: 12513833.
- Yang H, Wang S, Yin H. [P21(WAF1) inhibits the growth of leukemia cell line K562 and decreases its sensitivity to Vp16]. Zhonghua Xue Ye Xue Za Zhi 23(1):19-22, 2002. PMID: 12015083.
- Yang H, Wang SW, Yin HJ. [p21(WAF1) Gene Transfection Inhibits Proliferation of Leukemia Cell Line K562]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 9(2):115-118, 2001. PMID: 12578615.
- Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN. Blood. e-Pub 2017. PMID: 28774880.
- Yang H, Fang Z, Wei Y, Bohannan ZS, Gañán-Gómez I, Pierola AA, Paradiso LJ, Iwamura H, Garcia-Manero G. Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. Leuk Res 59:85-92. e-Pub 2017. PMID: 28599189.
Abstracts
- Wei Y, Jia Y, Zheng H, Hui Yang, Bohannan ZS, Lee J, Zhao C, Bueso-Ramos CE, Chamseddine AN, Garcia-Manero G. Pharmacological Inhibition of Histone Demethylase JMJD3 Reduces Leukemia Cell Survival and Represses Production of the Cytokine CCL2 in MDS/AML. Blood 126(23):5219, 2015.
- Chamseddine AN, Wei Y, Cabrero M, Ganan-Gomez I, Colla C, Takahashi K, Yang H, Estecio MR, Bohannan ZS, Pierce S, Bueso-Ramos CE, Kantarjian HM, Jabbour E, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes. Blood 126(23):5227, 2015.
- Carter BZ, Kornblau SM, Mak PY, Yang H, Qiu Y, Jiang X, Coombes K, Zhang N, Garcia-Manero G, Andreeff M. Focal Adhesion Kinase As a Potential Target in AML and MDS. Blood 126(23):3680, 2015.
- Garcia-Manero G, Yang H, Fang Z, DiNardo CD, Jabbour E, Pemmaraju N, Delumpa R, Loiselle C, Denton S, Smith W, Iwamura H, Gipson T, Rosner M, Madden T, Myers TJ, Paradiso LJ. Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures. Blood 126(23):3800, 2015.
- Wei Y, Cabrero M, Jia Y, Zheng H, Yang H, Fang Z, Bohannan Z, Chen R, Wang H , Colla S, Wang X, Garcia-Manero G. Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood 124(124):3241, 2014.
- DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva N, Pemmaraju N, Yang H, Wei Y, Wierda WG, Bueso-Ramos CE, Patel KP, Cortes JE, Ravandi F, Kantarjian H, Garcia-Manero G. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood 124(21):164, 2014.
- Colla S, Ong D, Ogoti Y, Marchesini M, Mistry N, Clise-Dwyer K, Storti P, Viale A, Wei Y, Giuliani N, Yang H, D'Anca M, Estecio M R, Liang , Kantarjian HM, Wang AY, Chin L, Bueso-Ramos CE, Garcia-Manero G, DePinho R. A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome. Blood 124(21):523, 2014.
- ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Marchesini M, Storti P, Ogoti Y, D'Anca M, Nezi L, Wei Y, Yang H, Ong D, Neri A, Giuliani N, Garcia-Manero G, DePinho R, Colla S. Blood 124(21):30, 2014.
- Estecio MR, Maddipoti S, DiNardo CD, Yang H, Stevenson WS, Bueso-Ramos CE, Pierce S, Wei Y, Garcia-Manero G. Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype 124(21):3548, 2014.
- Gañán-Gómez I, Ogoti Y, Marchesini M, Yue Wei, Yang H, Jiang S, Bao N, Bueso-Ramos CE, Garcia-Manero G, Colla S. Effect of Azacytidine on the Hematopoietic Stem and Progenitor Cell Compartments of MDS Mouse Models: Unveiling the Mechanisms of Remission and Relapse. Blood 126(23):2852, 2014.
- Wei Y, Yu J, Zhen H, Yang H, Chen R, Wang H, Wang X, Garcia-Manero G. Assessment Of EZH2 Expression In CD34+ Bone Marrow Progenitor Cells Of Patients Of Myelodysplastic Syndromes (MDS). Blood 122(21):2805, 2013.
- Yue Wei, Yu Jia, Hong Zheng, Hui Yang, Zhihong Fang, Simona Colla, Guillermo Garcia-Manero. Down-Regulated Expression Of Protection Of Telomeres 1 (POT1) Gene In Bone Marrow Hematopoietic Progenitor Cell Compartment Has Prognostic Value In Myelodysplastic Syndromes (MDS). Blood 122(21):1511, 2013.
- Wei Y, Jia Y , Zheng H, Yang Hui, Fang Z, Colla S, Garcia-Manero G. Expression Of Immune Checkpoints PD-L1, PD-L2, PD-1 and CTLA4 Predict For Prognosis and Resistance To Hypomethylating Agents (HMAs) In Myelodysplastic Syndromes (MDS) 122(21):2767, 2013.
- Ganan-Gomez I, Wei Y, Yang H, Boyano-Adánez MC, Garcia-Manero G. Overexpression Of Mir-125a In Bone Marrow CD34+ cells Of Patients With Myelodysplastic Syndrome Is Correlated To a Poor Prognosis and May Contribute To The Pathogenesis Of The Disease Through The Modulation Of NF-Kb Activation and Enhancement Of Differentiation Arrest. Blood 122(21):5206, 2013.
- Kampen KR, Scherpen FJG, Garcia-Manero G, Hui Yang, Kornblau SM, de Bont E. EphB1 Downregulation In Acute Myeloid Leukemia: Suppressing p53-Dependent DNA Damage Control System 122(21):2484, 2013.
- Xiaoying L, Tung S, Setoyama T, D’Abundo L, Simon R, Yang H, Yvon E, Shah N, Yang H, Garcia-Manero G, McNiece IK, Rezvani K, Calin G, Shpall EJ, Parmar S. FOXP3 Is a Direct Target Of miR15a/16 in Umbilical Cord Blood Regulatory T Cells. Blood 122(21):3261, 2013.
- Wei Y, Bueso-Ramos CE, Yang H, Jia H, Zheng H, Colla S, Nguyen M, Fernandez M, Kantarjian HM, Garcia-Manero G. Serum Amyloid Protein A 1 (hSAA1) Is Overexpressed in Myelodysplastic Syndromes and Potentially Mediates Toll-Like Receptor 2 Innate Immunity Signaling in CD34+ Hematopoietic Stem Cells. Blood (ASH Annual Meeting Abstracts) 120(1703), 2012.
- Dimicoli S, Wei Y, Chen R, Beso-Ramos CE, Pierce SA, Yang H, Jia Y, Zheng H, Fang Z, Ganan-Gomez I, Nguyen M, Fernandez M, Kanrjian HM, Garcia-Manero G. Toll-Like Receptor (TLR) Signaling Adaptor Protein MYD88 in Myelodysplastic Syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 120(556), 2012.
- Yang H, Bueso-Ramos CE, Pierce SA, Wei Y, Fang Z, Nguyen M, Fernandez M, Cardenas-Turanzas M, Kantarjian HM, Garcia-Manero G. Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients. Blood (ASH Annual Meeting Abstracts) 120(3845), 2012.
- Attieh Y, Wei Y, Yang H, Jia Y, Zheng H, Fang Z, Kantarjian HM Garcia-Manero G. Low Frequency of Molecular Alterations of H3.3-Atrx-Daxx Chromatin Remodeling Component Genes in Myelodysplastic Syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 120(3844), 2012.
- Wei Y, Chen R, Dimicoli S, Bueso-Ramos CE, Neuberg DS, Pierce SA, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Fernandez M, Wang SA, Kantarjian HM, Garcia-Manero G. Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 120(1700), 2012.
- Yang H, Bueso-Ramos CE, Parmar S, Wei Y, Fang Z, Nguyen M, Fernandez M, Pierce SA, Geng Z, Kantarjian HM, Corttes JE, Garcia-Manero G. Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to HMAs. Blood (ASH Annual Meeting Abstracts) 120(3810), 2012.
- Yang H, Bueso-Ramos CE, Pierce SA, Wei Y, Fang Z, Nguyen M, Fernandez M, Cardenas-Turanzas M, Kantarjian HM, Garica-Manero G. Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 120(2827), 2012.
Grant & Contract Support
Title: | MDS Clinical Research Consortium |
Funding Source: | Aplastic Anemia & MDS International Foundation supported by the Evans Foundation |
Role: | Co-Investigator |
Title: | Towards the cure of myelodysplastic syndrome: interfering with innate immunity alterations in human and mouse systems |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |